Orphan Drugs In Asia-pacific: From Designation To Pricing, Funding & Market Access Aarkstore Enterpr

A major new report Orphan Drugs in Asia-Pacific: From designation to pricing

, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commercialisation of rare disease treatments. Singapores Medicines (Orphan Drug) Exemption Order of 1991 was the first legislation anywhere to follow the US Orphan Drug Act, with the other four Asia-Pacific countries also implementing orphan-promoting measures ahead of the EU.

Rare diseases are collectively not that rare, indeed 6-10% of people will suffer from one at some point in life. Asia-Pacific contains nearly two-thirds of the worlds population, and should offer great potential to companies developing orphan drugs. But clinical need alone does not mean that adequate money for diagnosis and treatment will be made available.

The report describes the processes for obtaining orphan product designation, what can be omitted from the standard dossier to obtain marketing authorisation, and provides full details of the regulatory bodies and timelines involved. The main emphasis though is not on registration but on market access, which for products like orphan drugs that often carry premium prices, means eligibility for reimbursement or other sources of public funds.

Based on extensive research, including fieldwork in Tokyo and Seoul in November 2009 to capture detail, understanding and all the latest trends, the report includes:

The incentives on offer to orphan drug sponsors.

How P&R processes work specifically for orphan drugs.

The role of HTA and risk sharing as levers to obtain reimbursement.

Where special funding schemes operate and how to access them.

13 case studies on the P&R history of 12 different orphan drugs in 5 countries.

How much patients are expected to contribute to the cost of their treatment.

Listings of designated and approved orphan drugs.

Comparisons between countries with orphan drug policies and those without.

Contact details of the main rare disease patient organisations.

Learn which of the Asia-Pacific countries ...offers the most comprehensive programme for the management of rare diseaseoften enjoys higher orphan drug prices than the US...has the most orphan drugs on the market and reimbursedpromotes the development of rare disease medical devices as well as drugswhere named patient imports are discouraged by rare disease patient representatives.

Table of Contents :

1. Introduction

2. Japan

2.1 Healthcare and Health Insurance System

2.2 Orphan Drug Legislation

For more information please contact :

http://www.aarkstore.com/reports/Orphan-Drugs-in-Asia-Pacific-From-designation-to-pricing-funding-market-access-39545.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

http://www.aarkstore.com

by: Aarkstore Enterprise

POST COMMENT

When Does It Make Sense to Move Your Organization to a True Nonprofit Accounting System? Current Age Email Marketing - Must Haves How to Pick the Right Product to Market Online New Blog Blueprint Review: Blogging for Profit Starts Out With A Good Long Term Plan Franchise Marketing - Don't Give it Away Silver Lotto System Scam Aarkstore Enterprise- Barber Shops Market Research Aggregator We Give You Optimized Website, You Get Optimized Profit We Make You As Fierce As Your Market Seo Marketing Services Access To Hospital Pharmaceutical Markets In The United Kingdom- Aarkstore Enterprise Could Telemarketing Fraud Happen To You? El Marketing Con Artículos Y El Posicionamiento Web